change direction new plan alter arrows move reprioritize
Biotech

AstraZeneca relaxed about relaxin drug's poor efficacy in ph. 2

AstraZeneca executives have told Fierce Biotech they still see potential in harnessing the relaxin hormone to treat heart failure.
Darts failing to hit bullseye

2025's top 10 clinical trial flops

Feb 9, 2026 3:00am
How AI Is reshaping clinical trials and market access

How AI Is reshaping clinical trials and market access

Feb 9, 2026 8:00am
Image of a neon sign with the word no lit up next to an unlit yes

FDA rejects Regenxbio's Hunter syndrome gene therapy

Feb 9, 2026 4:05pm
Article Primary Image 1jpg

The Data Multiplier Effect: The 4 Forces Changing Biometrics

Feb 9, 2026 8:00am
Completing steps towards success checkmark on cubes symbolizing progress

Nektar eczema asset 'checked all of the boxes' in phase 2

Feb 10, 2026 10:55am
More News

AstraZeneca's oral GLP-1 scored phase 2 wins, but no data yet

Feb 10, 2026 9:58am

Merck teams up with British medtech Calla Lily

Feb 10, 2026 9:40am

Evommune's Dupixent-like eczema data drive 75% stock rally

Feb 10, 2026 9:31am

Kailera, Hengrui to advance oral obesity drug into 2 new trials

Feb 10, 2026 9:25am